

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING

To:

YOON, Dong-Yol

9th Fl., Yosam Bldg., 648-23 Yoksam-dong, Kangnam-ku,
Seoul 135-748, Republic of Korea

PCT

WRITTEN OPINION

(PCT Rule 66)



Date of mailing
(day/month/year) 23 MARCH 2005 (23.03.2005)

Applicant's or agent's file reference
PCT-031226

REPLY DUE within 1 months from
the above date of mailing

International application No.

PCT/KR2003/001889

International filing date (day/month/year)

16 SEPTEMBER 2003 (16.09.2003)

Priority date (day/month/year)

26 DECEMBER 2002 (26.12.2002)

International Patent Classification (IPC) or both national classification and IPC

IPC7 C07J 17/00

Applicant

AMOREPACIFIC CORPORATION et al

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☐ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

When ? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d)

How ? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3
For the form and the language of the amendments, see Rules 66.8 and 66.9

Also For an additional opportunity to submit amendments, see Rule 66.4.
For an examiner's obligation to consider amendments and/or arguments, see Rule 66.4bis
For an informal communication with the examiner, see Rule 66.6

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 16 APRIL 2005 (16.04.2005)

Name and mailing address of the IPEA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

PARK, JEONG UNG

Telephone No. 82-42-481-8159



WRITTEN OPINION

International application No.

PCT/KR2003/001889

I. Basis of the opinion

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the claims:
 pages _____, as originally filed
 pages _____, as amended (together with any statement) under Article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the drawings:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language English which is

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☒ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheet/fig. _____

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed."

WRITTEN OPINION

International application No.

PCT/KR2003/001889

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-3	YES
	Claims	4	NO
Inventive step (IS)	Claims	1-3	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-4	YES
	Claims		NO

2. Citations and explanations

본 발명은 20-O-beta-D-글루코피라노실-20(S)-프로토파낙사디올 (화합물 K) 로 이루어진 히알루론산 생성촉진제를 유효성분으로 하는 노화방지제에 관한 것이다.

D1: KR 2003-65273 A (Il Hwa Co., Ltd.) 06 Aug. 2003

D2: KR 2003-80429 A (Pacific Corporation) 17 Oct. 2003

D3: KR 2003-60017 A (Pacific Corporation) 12 Jul. 2003

D4: KR 2003-60018 A (Pacific Corporation) 12 Jul. 2003

1. 신규성 및 진보성

본원발명의 특허청구범위 제4항은 화합물 K를 함유하는 피부노화 방지제를 청구하고 있으나, 문헌 D1-D4에는 동일 화합물 K를 사용한 피부노화 방지제를 청구하고 있어, 본원발명은 선행기술 D1-D4와 동일한 발명으로 인정됨 [PCT Article 33(2)]. 본원발명의 특허청구범위 제1항 내지 제3항은 신규성 및 진보성이 있는 것으로 인정됨 [PCT Article 33(2), PCT Article 33(3)].

2. 산업상 이용가능성

인정됨, [PCT Article 33(4)].